The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 03, 2022

Filed:

Jul. 14, 2017
Applicants:

Biontech Rna Pharmaceuticals Gmbh, Mainz, DE;

Tron—translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg, Mainz, DE;

Inventors:

Ugur Sahin, Mainz, DE;

Heinrich Haas, Mainz, DE;

Annette Vogel, Mainz, DE;

Daniel Zucker, Mainz, DE;

Stephanie Erbar, Mainz, DE;

Kerstin Walzer, Seeheim-Jugenheim, DE;

Anne Schlegel, Düsseldorf, DE;

Sebastian Hörner, Mainz, DE;

Sebastian Kreiter, Mainz, DE;

Mustafa Diken, Mainz, DE;

Jorge Moreno Herrero, Mainz, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01);
Abstract

The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.


Find Patent Forward Citations

Loading…